Claude Sardet currently serves as Président CSS2 INSERM Cancer & Génétique at Inserm since January 2022. Prior to this, Claude held the position of DRCE CNRS and Head of the Inserm Team "Genetic and Phenotypic Plasticity of Cancer" at the IRCM U1194 since January 2015, where Claude was also Director until July 2022. Claude's extensive career includes roles as DR CNRS at the Institut de Génétique Moléculaire de Montpellier (IGMM) and as a WHO and NIH Fogarty Fellow at the Whitehead Institute, MIT. Claude's foundational experience began in research laboratories in Nice and Strasbourg, following an engineering education at INSA Lyon.
This person is not in any teams
IRCM - Institut de Recherche en Cancérologie de Montpellier
The Cancer Research Institute of Montpellier U1194 jointly operated by Inserm, University of Montpellier and Institut du Cancer de Montpellier (CLCC) 220 scientists and support personnel 17 research teams sharing 5000 m2 of lab space Excellent core facilities, many being part of the shared facilities network Montpellier BioCampus Biotech spin-offs Ground breaking research in basic and translational oncology developed in close collaboration with clinical departments and clinical research at ICM One central theme and two unifying programs : Molecular Targets and Cancer Therapy 1. Plasticity of solid tumors : from discoveries to personalized medecine 2. Therapeutic Antibodies in Cancer Treatment : Innovation, design and biological response